CClinicalTrials.gg
Status unknownNCT04549623Updated Oct 14, 2020

End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography

An interventional study of Novel end-tidal CO2 monitoring device and SpO2 and respiratory motion monitoring in Endoscopic Ultrasonography, Sedation and Monitoring, sponsored by Changhai Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-10-14.

Sponsored by Changhai Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To meet the needs of both operators and patients, moderate and deep sedation has been widely used in digestive endoscopy, which is invasive and painful. With its pleasant effects, sedation has complications nevertheless. And respiratory depression is the most common one, which makes respiratory monitoring significant. SpO2 and respiratory motion are regularly monitored without satisfying timeliness or sensitivity. Capnography with current device is only able to detect either oral or nasal breathing. The present study was designed to test the effect of the investigator's modified End-Tidal Carbon Dioxide (ETCO2) monitoring device for sedation during endoscopic ultrasonography-guided fine needle aspiration.

02

Conditions studied

  • Endoscopic Ultrasonography
  • Sedation
  • Monitoring
03

In context

Lead sponsor

Changhai Hospital is the lead sponsor of 342 studies on the registry; 133 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Scheduled for ultrasonography-guided fine needle aspiration
  • Adult patients aged 18 to 65 years
  • American Society of Anesthesiologists (ASA) Physical Status Classification I-III
  • Subjects provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Full stomach or upper gastrointestinal tract obstruction
  • Baseline pulse oximetric saturation (SpO2) \<95% while breathing room air
  • Obesity (BMI≥28kg/m2)or anticipated difficult airway
  • Cardiovascular or cerebrovascular events within 3 months
  • Pregnancy
  • Chronic opioid user
  • Allergic to anesthetics
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
480 participants (estimated)

Study arms

  • Experimental
    Group ETCO2

    Novel end-tidal carbon dioxide monitoring device is used for sedation.

    Device: Novel end-tidal CO2 monitoring device

  • Experimental
    Group Reg

    Peripheral oxygen saturation (SpO2) and respiratory motion are regularly monitored during sedation.

    Device: SpO2 and respiratory motion monitoring

Interventions

  • DeviceNovel end-tidal CO2 monitoring device

    Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.

  • DeviceSpO2 and respiratory motion monitoring

    Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.

06

What researchers measure

Primary outcomes

  1. Peripheral oxygen saturation

    Peripheral oxygen saturation is measured by pulse oximetry and hypoxemia is defined as SpO2≤91%

    Time frame: Across the sedation, assessed up to 2 hours

Secondary outcomes

  1. Arterial pO2 and pCO2

    The results of arterial blood gas measurements including partial pressure of oxygen (pO₂) and carbon dioxide (pCO₂)

    Time frame: 30 minutes after initiation of the sedation

  2. The numbers of the times of body movement

    The numbers of the times of any body movement across the procedure

    Time frame: From the completion of sedation to the completion of endosonography procedure, assessed up to 2 hours

  3. Incidence of hypertension and hypotension

    Hypertension or hypotension is defined as an increase or decrease in systolic blood pressure ≥20% compared to baseline values

    Time frame: From the completion of sedation to the completion of endosonography procedure, assessed up to 2 hours

  4. Recovery time

    Duration of the recovery from sedation

    Time frame: After termination of the sedation medication, assessed up to 2 hours

  5. Total dosage of propofol

    The patients are induced with 1.5\~2.5mg/kg and maintained with 6\~10mg/(kg•h) propofol. A propofol bolus dose range 0.2\~0.5 mg/kg will be administered when needed.

    Time frame: Across the sedation, assessed up to 2 hours

  6. Satisfaction score of the patients and endosonographers

    Satisfaction score of the patients and endosonographers regarding to the sedation quality measured by a 0-100 visual analogue scale (VAS). 100 refers to the highest satisfaction degree while 0 refers to the worst satisfaction degree.

    Time frame: Across the procedure, assessed up to 2 hours

07

Study locations

1 of 1 sites recruiting
  • Faculty of Anesthesiology, Changhai Hospital
    Shanghai, Shanghai 200433, China
    • Jia-feng Wang, M.D. · Contact · jfwang@smmu.edu.cn · +86-21-31161853
    • Jia-feng Wang, M.D. · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04549623
Lead sponsor
Changhai Hospital
Responsible party
Jia-feng Wang (Principal Investigator, Changhai Hospital) — Principal investigator
First posted
Sep 16, 2020
Start date
Sep 27, 2020
Primary completion
Dec 2021 (estimated)
Completion
Feb 2022 (estimated)
Last update
Oct 14, 2020

Study contacts

Jia-feng Wang, MD
Contact
jfwang@smmu.edu.cn
+862131161869

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion